• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP
Click for more information
0.00% 21.0¢

CYNATA THERAPEUTICS LIMITED - News & Media

Market Cap $37.72M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Articles & Videos

Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

20 Mar 2024 10:44 (AEDT)

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on graft versus host disease.

05 Mar 2024 15:38 (AEDT)

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase II clinical trial using its drug candidate, CYP-001.

07 Dec 2023 13:04 (AEDT)

Cynata Therapeutics (AX:CYP) announces CEO succession and board changes

Cynata Therapeutics (ASX:CYP) has appointed Dr Kilian Kelly as its CEO and Managing Director, effective from July 1.

30 Jun 2023 15:15 (AEST)

Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

Cynata Therapeutics (ASX:CYP) has received approval to launch a proposed phase two clinical trial of acute graft-versus-host disease.

30 Jan 2023 14:49 (AEDT)



(20min delay)
Last
21.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $37.72M
Open High Low Value Volume
20.0¢ 21.0¢ 20.0¢ $4.156K 20.74K

Buyers (Bids)

No. Vol. Price($)
1 20000 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 54635 3
View Market Depth
Last trade - 15.43pm 26/04/2024 (20 minute delay) ?
CYP (ASX) Chart

Top Stories

Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure

In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
Lithium Universe reveals plan to fill a 'gap' in the North American market Lithium Universe has flagged its Québec Lithium Processing Hub in Canada as a key producer of battery-grade lithium to the North American market..
Crypto world awaits overnight Bitcoin halving event The four-yearly Bitcoin halving is set to happen in the early hours of tomorrow morning (Saturday, April 20) - it's an event that industry leader Swyftx likened to 'the Olympic Games for the crypto industry'.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Are there gains to be made with the grocery giants? There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.